{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:16:51Z","timestamp":1771719411745,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89931","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:44:43Z","timestamp":1755045883000},"source":"Crossref","is-referenced-by-count":1,"title":["Downstream Outcomes of Elevated Prostate-Specific Antigen (PSA) Detected Through Routine Screening in Men Aged 55\u201370: A 10-Year Retrospective Study"],"prefix":"10.7759","author":[{"given":"Mayank","family":"Korpal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Jaddou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"PSA test. (2025). https.\/\/www.mayoclinic.org\/tests-procedures\/psa-test\/about\/pac-20384731."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati R","year":"2013","unstructured":"Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013, 158:145-53. 10.7326\/0003-4819-158-3-201302050-00003","journal-title":"Ann Intern Med"},{"key":"ref3","article-title":"Adenocarcinoma of the prostate (Article in Czech)","volume":"137","author":"Dvor\u00e1cek J","year":"1998","unstructured":"Dvor\u00e1cek J. Adenocarcinoma of the prostate (Article in Czech). Cas Lek Cesk. 1998, 137:515-21.","journal-title":"Cas Lek Cesk"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic D","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, et al.. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018, 362:k3519. 10.1136\/bmj.k3519","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb S","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, et al.. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014, 65:1046-55. 10.1016\/j.eururo.2013.12.062","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08214.x","article-title":"Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial","volume":"102","author":"Grubb RL 3rd","year":"2008","unstructured":"Grubb RL 3rd, Pinsky PF, Greenlee RT, et al.. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008, 102:1524-30. 10.1111\/j.1464-410X.2008.08214.x","journal-title":"BJU Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1468-9","article-title":"What happens after an elevated PSA test: the experience of 13,591 veterans","volume":"25","author":"Zeliadt SB","year":"2010","unstructured":"Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med. 2010, 25:1205-10. 10.1007\/s11606-010-1468-9","journal-title":"J Gen Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.323","article-title":"Five-year downstream outcomes following prostate-specific antigen screening in older men","volume":"173","author":"Walter LC","year":"2013","unstructured":"Walter LC, Fung KZ, Kirby KA, et al.. Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med. 2013, 173:866-73. 10.1001\/jamainternmed.2013.323","journal-title":"JAMA Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2336","article-title":"PSA screening among elderly men with limited life expectancies","volume":"296","author":"Walter LC","year":"2006","unstructured":"Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006, 296:2336-42. 10.1001\/jama.296.19.2336","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman DC","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al.. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018, 319:1901-13. 10.1001\/jama.2018.3710","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: a literature review","volume":"128","author":"Lillard JW Jr","year":"2022","unstructured":"Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: a literature review. Cancer. 2022, 128:3787-95. 10.1002\/cncr.34433","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed H.U","unstructured":"Ahmed H.U, El-Shater Bosaily A, Brown L.C, et al.. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 389:815-22. 10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13793","article-title":"Prostate cancer screening practices in a large, integrated health system: 2007-2014","volume":"120","author":"Misra-Hebert AD","year":"2017","unstructured":"Misra-Hebert AD, Hu B, Klein EA, Stephenson A, Taksler GB, Kattan MW, Rothberg MB. Prostate cancer screening practices in a large, integrated health system: 2007-2014. BJU Int. 2017, 120:257-64. 10.1111\/bju.13793","journal-title":"BJU Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei JT","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, et al.. Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening. J Urol. 2023, 210:46-53. 10.1097\/JU.0000000000003491","journal-title":"J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz L","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P, et al.. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015, 33:272-7. 10.1200\/JCO.2014.55.1192","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5757","article-title":"Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts","volume":"360","author":"Seibert TM","year":"2018","unstructured":"Seibert TM, Fan CC, Wang Y, et al.. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018, 360:j5757. 10.1136\/bmj.j5757","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/396379-downstream-outcomes-of-elevated-prostate-specific-antigen-psa-detected-through-routine-screening-in-men-aged-55-70-a-10-year-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:44:44Z","timestamp":1755045884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/396379-downstream-outcomes-of-elevated-prostate-specific-antigen-psa-detected-through-routine-screening-in-men-aged-55-70-a-10-year-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.89931","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}